Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Apr 3

PMID 33800446

Citations 16

Authors

Anna Wolska

Mart Reimund

Denis O Sviridov

Marcelo J Amar

Alan T Remaley

Affiliations

Soon will be listed here.

Abstract

Since the seminal breakthrough of treating diabetic patients with insulin in the 1920s, there has been great interest in developing other proteins and their peptide mimetics as therapies for a wide variety of other medical disorders. Currently, there are at least 60 different peptides that have been approved for human use and over 150 peptides that are in various stages of clinical development. Peptides mimetic of the major proteins on lipoproteins, namely apolipoproteins, have also been developed first as tools for understanding apolipoprotein structure and more recently as potential therapeutics. In this review, we discuss the biochemistry, peptide mimetics design and clinical trials for peptides based on apoA-I, apoE and apoC-II. We primarily focus on applications of peptide mimetics related to cardiovascular diseases. We conclude with a discussion on the limitations of peptides as therapeutic agents and the challenges that need to be overcome before apolipoprotein mimetic peptides can be developed into new drugs.

Citing Articles

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?.

Lan N, Watts G Curr Atheroscler Rep. 2025; 27(1):35.

PMID: 40009132 PMC: 11865134. DOI: 10.1007/s11883-025-01281-3.

High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches.

He S, Li X, He Y, Guo L, Dong Y, Wang L Nat Commun. 2025; 16(1):1061.

PMID: 39870661 PMC: 11772610. DOI: 10.1038/s41467-025-56223-z.

Missing Regulation Between Genetic Association and Transcriptional Abundance for Hypercholesterolemia Genes.

Hakim A, Connally N, Schnitzler G, Cho M, Jiang Z, Sunyaev S Genes (Basel). 2025; 16(1).

PMID: 39858631 PMC: 11764661. DOI: 10.3390/genes16010084.

Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes.

Stepanova N Biomedicines. 2024; 12(10).

PMID: 39457689 PMC: 11505255. DOI: 10.3390/biomedicines12102377.

Inflammatory and Immune Mechanisms for Atherosclerotic Cardiovascular Disease in HIV.

Hmiel L, Zhang S, Obare L, Santana M, Wanjalla C, Titanji B Int J Mol Sci. 2024; 25(13).

PMID: 39000373 PMC: 11242562. DOI: 10.3390/ijms25137266.

References

Sviridov D, Ikpot I, Stonik J, Drake S, Amar M, Osei-Hwedieh D . Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Commun. 2011; 410(3):446-51. PMC: 3253552. DOI: 10.1016/j.bbrc.2011.05.154. View

Marais A . Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019; 51(2):165-176. DOI: 10.1016/j.pathol.2018.11.002. View

Zdunek J, Martinez G, Schleucher J, Lycksell P, Yin Y, Nilsson S . Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Biochemistry. 2003; 42(7):1872-89. DOI: 10.1021/bi0267184. View

Datta G, Garber D, Chung B, Chaddha M, Dashti N, Bradley W . Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res. 2001; 42(6):959-66. View

Watson C, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I . Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2010; 52(2):361-73. PMC: 3023557. DOI: 10.1194/jlr.M011098. View

Wolska A, Yang Z, Remaley A . Hypertriglyceridemia: new approaches in management and treatment. Curr Opin Lipidol. 2020; 31(6):331-339. PMC: 7770610. DOI: 10.1097/MOL.0000000000000710. View

Mahley R, Weisgraber K, Innerarity T . Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta. 1979; 575(1):81-91. DOI: 10.1016/0005-2760(79)90133-4. View

Mahley R . Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016; 94(7):739-46. PMC: 4921111. DOI: 10.1007/s00109-016-1427-y. View

Zhao W, Du F, Zhang M, Sun S, Yu H, Fan D . A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Exp Biol Med (Maywood). 2011; 236(12):1468-76. DOI: 10.1258/ebm.2011.011169. View

10.

Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R . Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol. 2013; 33(9):2202-11. DOI: 10.1161/ATVBAHA.113.301981. View

11.

Souza A, Bocharov A, Baranova I, Vishnyakova T, Huang Y, Wilkins K . Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation. Kidney Int. 2016; 89(4):809-22. PMC: 4800337. DOI: 10.1016/j.kint.2015.12.043. View

12.

Buga G, Frank J, Mottino G, Hakhamian A, Narasimha A, Watson A . D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res. 2007; 49(1):192-205. DOI: 10.1194/jlr.M700433-JLR200. View

13.

Pownall H, Rosales C, Gillard B, Ferrari M . Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism. Methodist Debakey Cardiovasc J. 2016; 12(3):146-150. PMC: 5098571. DOI: 10.14797/mdcj-12-3-146. View

14.

Hafiane A, Johansson J, Genest J . ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. Can J Cardiol. 2019; 35(6):770-781. DOI: 10.1016/j.cjca.2019.02.018. View

15.

Remaley A, Stonik J, Demosky S, Neufeld E, Bocharov A, Vishnyakova T . Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001; 280(3):818-23. DOI: 10.1006/bbrc.2000.4219. View

16.

Yao X, Dai C, Fredriksson K, Dagur P, McCoy J, Qu X . 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol. 2010; 186(1):576-83. PMC: 3012266. DOI: 10.4049/jimmunol.1001534. View

17.

Anantharamaiah G, Garber D, Goldberg D, Morrel E, Datta G, Palgunachari M . Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques. J Lipid Res. 2018; 59(11):2075-2083. PMC: 6210918. DOI: 10.1194/jlr.M085985. View

18.

Gibson C, Kerneis M, Yee M, Daaboul Y, Korjian S, Poyan Mehr A . The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2018; 208:81-90. DOI: 10.1016/j.ahj.2018.11.008. View

19.

Navab M, Anantharamaiah G, Reddy S, Hama S, Hough G, Grijalva V . Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004; 109(25):3215-20. DOI: 10.1161/01.CIR.0000134275.90823.87. View

20.

Komatsu T, Sakurai T, Wolska A, Amar M, Sakurai A, Vaisman B . Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice. J Nutr Metab. 2019; 2019:7078241. PMC: 6377985. DOI: 10.1155/2019/7078241. View